Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response

Cell Reports

Volumn 11, Issue 6, 2015, Pages 957-966

  Xia, Xiaojun ^a   Mai, Junhua ^a   Xu, Rong ^a,e   Perez, Jorge Enrique Tovar ^a   Guevara, Maria L ^a   Shen, Qi ^a   Mu, Chaofeng ^a   Tung, Hui Ying ^b   Corry, David B ^b   Evans, Scott E ^c   Liu, Xuewu ^a   Ferrari, Mauro ^a,d   Zhang, Zhiqiang ^a   Li, Xian Chang ^a   Wang, Rong Fu ^a   Shen, Haifa ^a,d  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; IMMUNOLOGICAL ADJUVANT; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POROUS SILICON NANOPARTICLE; PROTEIN MAVS; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IPS-1 PROTEIN, MOUSE; MICROSPHERE; OVALBUMIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SILICON; TICAM-1 PROTEIN, MOUSE; TUMOR ANTIGEN; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; FEMALE; IMMUNOSTIMULATION; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MAMMARY NEOPLASM; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; NEOPLASM; PATHOLOGY; POROSITY; SIGNAL TRANSDUCTION;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; IMMUNITY, INNATE; INTERFERON TYPE I; MAMMARY NEOPLASMS, ANIMAL; MICE, INBRED C57BL; MICROSPHERES; NEOPLASMS; OVALBUMIN; PHAGOCYTOSIS; POROSITY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SILICON; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84929294202     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.04.009     Document Type: Article

References (50)

1. Ambrosino E., Spadaro M., Iezzi M., Curcio C., Forni G., Musiani P., Wei W.Z., Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 2006, 66:7734-7740.
2. Assudani D., Cho H.I., DeVito N., Bradley N., Celis E. Invivo expansion, persistence, and function of peptide vaccine-induced CD8 Tcells occur independently of CD4 Tcells. Cancer Res. 2008, 68:9892-9899.
3. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
4. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
5. Bos P.D., Plitas G., Rudra D., Lee S.Y., Rudensky A.Y. Transient regulatory Tcell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J.Exp. Med. 2013, 210:2435-2466.
6. Burgdorf S., Schölz C., Kautz A., Tampé R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 2008, 9:558-566.
7. Chen X., Iliopoulos D., Zhang Q., Tang Q., Greenblatt M.B., Hatziapostolou M., Lim E., Tam W.L., Ni M., Chen Y., et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature 2014, 508:103-107.
8. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
9. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
10. Dave B., Granados-Principal S., Zhu R., Benz S., Rabizadeh S., Soon-Shiong P., Yu K.D., Shao Z., Li X., Gilcrease M., et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc. Natl. Acad. Sci. USA 2014, 111:8838-8843.
11. Dougan M., Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 2009, 27:83-117.
12. Duggan J.M., You D., Cleaver J.O., Larson D.T., Garza R.J., Guzmán Pruneda F.A., Tuvim M.J., Zhang J., Dickey B.F., Evans S.E. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J.Immunol. 2011, 186:5916-5926.
13. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., Seamone M.E., Vilaysane A., Mucsi A.D., Fong Y., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 2011, 17:479-487.
14. Fric J., Zelante T., Ricciardi-Castagnoli P. Phagocytosis of particulate antigens-all roads lead to calcineurin/NFAT signaling pathway. Front. Immunol. 2014, 4:513.
15. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ Tcell responses through CD8alpha+ dendritic cells. J.Exp. Med. 2011, 208:2005-2016.
16. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14:1014-1022.
17. Gajewski T.F., Woo S.R., Zha Y., Spaapen R., Zheng Y., Corrales L., Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:268-276.
18. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N.Engl. J. Med. 2010, 363:711-723.
19. Holm C.K., Jensen S.B., Jakobsen M.R., Cheshenko N., Horan K.A., Moeller H.B., Gonzalez-Dosal R., Rasmussen S.B., Christensen M.H., Yarovinsky T.O., et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 2012, 13:737-743.
20. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
21. Kleindienst P., Brocker T. Endogenous dendritic cells are required for amplification of Tcell responses induced by dendritic cell vaccines invivo. J.Immunol. 2003, 170:2817-2823.
22. Lapteva N., Huang X.F. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin. Biol. Ther. 2010, 10:725-733.
23. Le Bon A., Tough D.F. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev. 2008, 19:33-40.
24. Lucchini F., Sacco M.G., Hu N., Villa A., Brown J., Cesano L., Mangiarini L., Rindi G., Kindl S., Sessa F., et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett. 1992, 64:203-209.
25. Marabelle A., Kohrt H., Sagiv-Barfi I., Ajami B., Axtell R.C., Zhou G., Rajapaksa R., Green M.R., Torchia J., Brody J., et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J.Clin. Invest. 2013, 123:2447-2463.
26. Millien V.O., Lu W., Shaw J., Yuan X., Mak G., Roberts L., Song L.Z., Knight J.M., Creighton C.J., Luong A., et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science 2013, 341:792-796.
27. Mills C.D., Kincaid K., Alt J.M., Heilman M.J., Hill A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J.Immunol. 2000, 164:6166-6173.
28. Mukai Y., Yoshinaga T., Yoshikawa M., Matsuo K., Yoshikawa T., Matsuo K., Niki K., Yoshioka Y., Okada N., Nakagawa S. Induction of endoplasmic reticulum-endosome fusion for antigen cross-presentation induced by poly (γ-glutamic acid) nanoparticles. J.Immunol. 2011, 187:6249-6255.
29. Nagata Y., Furugen R., Hiasa A., Ikeda H., Ohta N., Furukawa K., Nakamura H., Furukawa K., Kanematsu T., Shiku H. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J.Immunol. 1997, 159:1336-1343.
30. Nava-Parada P., Forni G., Knutson K.L., Pease L.R., Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res. 2007, 67:1326-1334.
31. Ng D., Gommerman J.L. The regulation of immune responses by DC derived type I IFN. Front. Immunol. 2013, 4:94.
32. O'Sullivan T., Saddawi-Konefka R., Vermi W., Koebel C.M., Arthur C., White J.M., Uppaluri R., Andrews D.M., Ngiow S.F., Teng M.W., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J.Exp. Med. 2012, 209:1869-1882.
33. Paulis L.E., Mandal S., Kreutz M., Figdor C.G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 2013, 25:389-395.
34. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J.Clin. Oncol. 2015, 10.1200/JCO.2014.59.4358.
35. Prinz M., Knobeloch K.P. Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front. Immunol. 2012, 3:67.
36. Sauer J.D., Sotelo-Troha K., von Moltke J., Monroe K.M., Rae C.S., Brubaker S.W., Hyodo M., Hayakawa Y., Woodward J.J., Portnoy D.A., Vance R.E. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the invivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 2011, 79:688-694.
37. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011, 11:805-812.
38. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., Singh M., O'Hagan D.T., Pétrilli V., Tschopp J., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA 2009, 106:870-875.
39. Shen H., Rodriguez-Aguayo C., Xu R., Gonzalez-Villasana V., Mai J., Huang Y., Zhang G., Guo X., Bai L., Qin G., et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin. Cancer Res. 2013, 19:1806-1815.
40. Shen J., Xu R., Mai J., Kim H.C., Guo X., Qin G., Yang Y., Wolfram J., Mu C., Xia X., et al. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 2013, 7:9867-9880.
41. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
42. Spaner D.E., Foley R., Galipeau J., Bramson J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 2008, 27:208-217.
43. Summers deLuca L., Ng D., Gao Y., Wortzman M.E., Watts T.H., Gommerman J.L. LTβR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ Tcells. Proc. Natl. Acad. Sci. USA 2011, 108:2046-2051.
44. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., Han H.D., Shahzad M.M., Liu X., Bhavane R., et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70:3687-3696.
45. Trombetta E.S., Mellman I. Cell biology of antigen processing invitro and invivo. Annu. Rev. Immunol. 2005, 23:975-1028.
46. Xu L.G., Wang Y.Y., Han K.J., Li L.Y., Zhai Z., Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 2005, 19:727-740.
47. Xu R., Huang Y., Mai J., Zhang G., Guo X., Xia X., Koay E.J., Qin G., Erm D.R., Li Q., et al. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 2013, 9:1799-1808.
48. Yang X., Zhang X., Fu M.L., Weichselbaum R.R., Gajewski T.F., Guo Y., Fu Y.X. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014, 25:37-48.
49. Yewdall A.W., Drutman S.B., Jinwala F., Bahjat K.S., Bhardwaj N. CD8+ Tcell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE 2010, 5:e11144.
50. Zhang Z., Kim T., Bao M., Facchinetti V., Jung S.Y., Ghaffari A.A., Qin J., Cheng G., Liu Y.J. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011, 34:866-878.